# Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

> **NCT03591770** · PHASE4 · TERMINATED · sponsor: **Boston Medical Center** · enrollment: 15 (actual)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **BIOLOGICAL:** SHINGRIX

## Key facts

- **NCT ID:** NCT03591770
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-31
- **Primary completion:** 2024-07-04
- **Final completion:** 2024-07-04
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Unable to recruit adequate numbers of participants to answer the research question.
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03591770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03591770, "Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03591770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*